Madrid

• HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended
  2023-508365-33-00 5 2019-04-09 Hereditary Transthyretin Amyloidosis
• A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended
  2023-505476-29-00 5 2019-04-05 Giant Cell Arteritis
• Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended
  2023-508832-68-00 9 2019-03-28 Recurrent or stage IVB cervical cancer
• A study on the safety, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide against chronic Hepati … Ended
  2024-512352-38-00 4 2019-03-28 Hepatitis B, Chronic
• Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma. Ended
  2023-507777-18-00 4 2019-03-19 Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL
• "Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients … Ended
  2023-510020-68-00 7 2019-03-18 Hepatitis B, Chronic
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on … Ended
  2023-509800-14-00 3 2019-02-25 extensive stage small cell lung cancer
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Ended
  2023-508207-21-00 9 2019-02-08 Advanced Malignant Tumors
• Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended
  2023-507330-24-00 9 2019-02-07 Chronic Graft Versus Host Disease (cGVHD)
• Phase 1 / 2 study of amcenestrant (SAR439859) single agent and in combination with other anti-cancer therapies in postmenopausal women with … Ended
  2024-512997-89-00 7 2019-01-29 Cancer
• Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma Ended
  2023-508127-13-00 4 2019-01-25 Adult patients with refractory or relapsed follicular lymphoma
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 5 2019-01-25 Adult patients with relapsed or refractory aggressive B-cell non-Hodgk
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• Study of subcutaneous nivolumab monotherapy with or without Recombinant Human Hyaluronidase PH20 (rHuPH20) Ended
  2023-503554-12-00 9 2019-01-09 lung cancer; kidney cancer; melanoma; liver cancer; colorectal cancer;
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung Cancer Ended
  2022-500990-16-00 4 2018-12-19 Stage IV non-small cell lung cancer
• A clinical study to investigate if the investigational products, called LN-144 and LN-145 (also known as Tumour Infiltrating Lymphocytes), a … Ended
  2024-510779-39-00 4 2018-12-19 Neoplasm
• A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in … Ended
  2024-512158-12-00 5 2018-12-14 Bladder Cancer Muscle-Invasive Bladder Cancer
• Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast can … Ended
  2023-508550-25-00 3 2018-12-10 Pre and post-menopausal women with resectable primary breast cancer an
• Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended
  2024-515040-23-00 4 2018-11-26 Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously tre
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum … Ended
  2023-509061-20-00 9 2018-11-22 Advanced solid tumors
• A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet … Ended
  2023-507312-13-00 5 2018-11-15 Multiple Myeloma

Showing 3,457–3,480 of 3,599 trials